Availability of large number of innovative recombinant proteins from various sources such as human and animal, lack of suitable alternative for basic protein related therapies research, coupled with increasing demand for biopharmaceutical products are the factors that are expected to drive growth of the recombinant protein market over the forecast period.
Moreover, key players are focusing on collaborations and acquisitions for drug discovery and development purposes. For instance, Crown Bioscience (CBI), Inc. entered into a collaboration with Jiangsu Qyun Bio-Pharmaceutical Co. Ltd. to develop CTLA-4 antibody, in 2017. Additionally, in 2016, CBI acquired PreClinOmics, Inc., an in vivo preclinical company that specializes in early research in cardiovascular and metabolic disease.
Major Company Profiles Covered in This Report: Crown Bioscience, Inc., ProSpec Tany TechnoGene, Ltd., BPS Bioscience, Inc., Sigma Aldrich Company Ltd., Novoprotein Scientific, PeproTech, Inc., Feldan Bio, Inc., BioVision, Inc., HumanZyme, Inc., and GenScript Biotech Corporation.
FREE | Request Sample is Available @
*The Sample only consist of Table of Content (ToC).
Research Framework of the actual report.
Research Methodology adopted for it.
Moreover, in the same year CBI launched six new recombinant cell lines, which include GITR, ICOS, CD137, CTLA-4, OX40, and RANK immune checkpoints and receptors for biological studies, drug discovery, and development. Furthermore, in 2012, ProSpec-Tany Technogene Ltd. and LifeMap Sciences, Inc., a wholly owned subsidiary of BioTime, Inc. entered into a definitive agreement to offer 1,000 recombinant proteins and antibodies, which can be used for stem cell research, drug discovery, and development biology. In addition, in 2014, BPS Bioscience, Inc. introduced 13 different mutant EZH2 complexes and two new assay kits for screening inhibitors of mutant EZH2.
Additionally, major players of the market are focusing on expanding their geographic presence, in order to strengthen their market position. For instance, in 2016, Sigma Aldrich Company Ltd. established nine new M Lab Collaboration Centers in Asia Pacific, North America, Europe, and Latin America for its life science business. The centers are expected to fuel growth of its recombinant protein business. Moreover, manufacturers are increasingly participating in international and national conferences, in order to promote their products.
For instance, Novoprotein Scientific, participated in AAPS National Biotechnology Conference, which was dedicated to recent developments of protein recombinants, globally in 2014. Moreover, in 2016, PeproTech, Inc. participated in Advances in Stem Cells and Regenerative Medicine conference held at EMBL, Heidelberg, Germany, in 2017. Furthermore, in 2016, Feldan Bio, Inc. and Elasmogen, a biopharmaceutical company signed an exclusive partnership for the development of intracellular biologics. Moreover, in 2017, BioVision Inc. launched Cas9 recombinant protein for genome editing. Cas9 protein of the CRISPR-Cas9 system is an RNA-guided DNA endonuclease enzyme, which aids in unwinding of genomic DNA complex.
Download Free PDF Brochure @